Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.32 |
| ▸ | BLM | P54132 | 2/20 | 0.32 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | UGT2B7 | P16662 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2708568 | 1.00 | GABRR1 (0.32) | GABRR1GABRR2BLMGABRR3LMNA | |
| SCHEMBL2706242 | 0.81 | GABRR1 (0.31) | GABRR1GABRR2BLMGABRR3LMNA | |
| SCHEMBL2706131 | 0.81 | GABRR1 (0.31) | GABRR1GABRR2BLMGABRR3LMNA | |
| SCHEMBL5689103 | 0.73 | UGT2B7 (0.32) | GABRR1GABRR2BLMGABRR3LMNA | |
| SCHEMBL9162494 | 0.72 | — | — | |
| SCHEMBL9162501 | 0.72 | — | — | |
| SCHEMBL5708369 | 0.72 | — | — | |
| SCHEMBL2425858 | 0.72 | — | — | |
| SCHEMBL5634431 | 0.72 | GRM2 (0.39) | GABRR1 | |
| SCHEMBL9164333 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9451784-B2 | Off-note blocking sensory organic compounds | GIVAUDAN S.A. (CH) | 2016-09-27 | — | — | US | claimed |
| US-20140194651-A1 | OFF-NOTE BLOCKING SENSORY ORGANIC COMPOUNDS | GIVAUDAN S.A. (CH) | 2014-07-10 | — | — | US | claimed |
| US-8409649-B2 | Off-note blocking sensory organic compounds | GIVAUDAN S.A. (CH) | 2013-04-02 | — | — | US | claimed |
| EP-2139841-B1 | OFF-NOTE BLOCKING SENSORY ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2012-05-02 | — | — | EP | claimed |
| US-20100284944-A1 | OFF-NOTE BLOCKING SENSORY ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2010-11-11 | — | — | US | claimed |
| EP-2139841-A1 | OFF-NOTE BLOCKING SENSORY ORGANIC COMPOUNDS | Givaudan SA (CH) | 2010-01-06 | — | — | EP | claimed |
| WO-2008119196-A1 | OFF-NOTE BLOCKING SENSORY ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2008-10-09 | — | — | WO | claimed |
| US-20200345049-A1 | COMPOSITIONS | GIVAUDAN SA (CH) | 2020-11-05 | — | — | US | disclosed |
| US-9451784-B2 | Off-note blocking sensory organic compounds | GIVAUDAN S.A. (CH) | 2016-09-27 | — | — | US | disclosed |
| US-9451784-B2 | Off-note blocking sensory organic compounds | GIVAUDAN S.A. (CH) | 2016-09-27 | — | — | US | disclosed |
| US-9451784-B2 | Off-note blocking sensory organic compounds | GIVAUDAN S.A. (CH) | 2016-09-27 | — | — | US | disclosed |
| EP-2850085-A1 | ANTIVIRAL COMPOUNDS INHIBITORS OF HCV NS5B | Gilead Pharmasset LLC (US) | 2015-03-25 | — | — | EP | disclosed |
| US-20140194651-A1 | OFF-NOTE BLOCKING SENSORY ORGANIC COMPOUNDS | GIVAUDAN S.A. (CH) | 2014-07-10 | — | — | US | disclosed |
| EP-2139841-B1 | OFF-NOTE BLOCKING SENSORY ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2012-05-02 | — | — | EP | disclosed |
| US-20100284944-A1 | OFF-NOTE BLOCKING SENSORY ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2010-11-11 | — | — | US | disclosed |
| US-20100284944-A1 | OFF-NOTE BLOCKING SENSORY ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2010-11-11 | — | — | US | disclosed |
| US-20100284944-A1 | OFF-NOTE BLOCKING SENSORY ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2010-11-11 | — | — | US | disclosed |
| EP-2139841-A1 | OFF-NOTE BLOCKING SENSORY ORGANIC COMPOUNDS | Givaudan SA (CH) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008119196-A1 | OFF-NOTE BLOCKING SENSORY ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119196-A1 | OFF-NOTE BLOCKING SENSORY ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100284944-A1 | OFF-NOTE BLOCKING SENSORY ORGANIC COMPOUNDS | SORD, OTC, ASPH | GABRR1 1209/4885GABRR2 1307/4885BLM 4829/4885 |
| US-20140194651-A1 | OFF-NOTE BLOCKING SENSORY ORGANIC COMPOUNDS | SORD, OTC, ASPH | GABRR1 1209/4885GABRR2 1307/4885BLM 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.